NEW YORK (GenomeWeb News) – Crescendo Bioscience today announced it has received clearance from New York to provide services to patients in the state. As a result, the company can now offer its rheumatoid arthritis test in New York.

The Wadsworth Center at the New York Department of Health, through its Clinical Laboratory Evaluation Program, issued a laboratory permit to the company. With today's approval, Crescendo Bio can now offer its test, called Vectra DA, in all 50 states in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.